| Metabolic signatures of exercise in human plasma GD Lewis, L Farrell, MJ Wood, M Martinovic, Z Arany, GC Rowe, A Souza, ... Science translational medicine 2 (33), 33ra37-33ra37, 2010 | 504 | 2010 |
| Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury GD Lewis, RU Wei, E Liu, E Yang, X Shi, M Martinovic, L Farrell, A Asnani, ... The Journal of clinical investigation 118 (10), 3503-3512, 2008 | 326 | 2008 |
| Application of metabolomics to cardiovascular biomarker and pathway discovery GD Lewis, A Asnani, RE Gerszten Journal of the American College of Cardiology 52 (2), 117-123, 2008 | 293 | 2008 |
| The zebrafish as a tool to identify novel therapies for human cardiovascular disease A Asnani, RT Peterson Disease models & mechanisms 7 (7), 763-767, 2014 | 200 | 2014 |
| Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase Y Liu, A Asnani, L Zou, VL Bentley, M Yu, Y Wang, G Dellaire, KS Sarkar, ... Science translational medicine 6 (266), 266ra170-266ra170, 2014 | 144 | 2014 |
| Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease AV Menon, J Liu, HP Tsai, L Zeng, S Yang, A Asnani, J Kim Blood, The Journal of the American Society of Hematology 139 (6), 936-941, 2022 | 117 | 2022 |
| Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis JR Power, J Alexandre, A Choudhary, B Ozbay, S Hayek, A Asnani, ... Circulation 144 (18), 1521-1523, 2021 | 109 | 2021 |
| Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor–associated myocarditis: a narrative review LH Lehmann, J Cautela, N Palaskas, AH Baik, WC Meijers, Y Allenbach, ... JAMA cardiology 6 (11), 1329-1337, 2021 | 98 | 2021 |
| A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy D Amgalan, TP Garner, R Pekson, XF Jia, M Yanamandala, V Paulino, ... Nature cancer 1 (3), 315-328, 2020 | 96 | 2020 |
| Impact of social vulnerability on comorbid cancer and cardiovascular disease mortality in the United States S Ganatra, SS Dani, A Kumar, SU Khan, R Wadhera, TG Neilan, ... Cardio Oncology 4 (3), 326-337, 2022 | 88 | 2022 |
| Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics RE Gerszten, A Asnani, SA Carr Circulation research 109 (4), 463-474, 2011 | 82 | 2011 |
| Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic S Ganatra, SS Dani, S Shah, A Asnani, TG Neilan, D Lenihan, B Ky, ... Trends in cardiovascular medicine 30 (6), 315-325, 2020 | 81 | 2020 |
| Cardiotoxicity of immunotherapy: incidence, diagnosis, and management A Asnani Current Oncology Reports 20, 1-7, 2018 | 77 | 2018 |
| Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial TG Neilan, T Quinaglia, T Onoue, SS Mahmood, ZD Drobni, HK Gilman, ... Jama 330 (6), 528-536, 2023 | 75 | 2023 |
| Fluoropyrimidine-associated cardiotoxicity J Kanduri, LA More, A Godishala, A Asnani Cardiology Clinics 37 (4), 399-405, 2019 | 67 | 2019 |
| Cardiotoxicities associated with immune checkpoint inhibitors S Yang, A Asnani Current Problems in Cancer 42 (4), 422-432, 2018 | 57 | 2018 |
| Preclinical models of cancer therapy–associated cardiovascular toxicity: a scientific statement from the American heart association A Asnani, JJ Moslehi, BB Adhikari, AH Baik, AM Beyer, RA de Boer, ... Circulation research 129 (1), e21-e34, 2021 | 54 | 2021 |
| 5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death LA More, S Lane, A Asnani Current cardiology reports 23, 1-8, 2021 | 47 | 2021 |
| Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis M Obasi, A Abovich, JB Vo, Y Gao, SI Papatheodorou, A Nohria, A Asnani, ... Cancer Causes & Control 32 (12), 1395-1405, 2021 | 41 | 2021 |
| Management of atrial fibrillation in patients taking targeted cancer therapies A Asnani, A Manning, M Mansour, J Ruskin, EP Hochberg, LM Ptaszek Cardio-Oncology 3, 1-10, 2017 | 40 | 2017 |
